Organogenesis Holdings (ORGO) Aperçu de l'action
Organogenesis Holdings Inc. est une société de médecine régénérative qui développe, fabrique et commercialise des produits pour les marchés du traitement avancé des plaies, de la chirurgie et de la médecine sportive aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
ORGO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Organogenesis Holdings Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$2.66 |
| Plus haut sur 52 semaines | US$7.08 |
| Plus bas sur 52 semaines | US$2.04 |
| Bêta | 1.31 |
| Variation sur 1 mois | 11.30% |
| Variation sur 3 mois | -28.11% |
| Variation sur 1 an | -7.32% |
| Variation sur 3 ans | -26.72% |
| Variation sur 5 ans | -83.79% |
| Évolution depuis l'introduction en bourse | -80.21% |
Nouvelles et mises à jour récentes
Recent updates
Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight
Summary Organogenesis Holdings Inc. is a cash-generative wound care leader trading at distressed multiples due to overestimated short-term reimbursement risks. PuraPly AM achieved statistically significant results in a randomized controlled trial for diabetic foot ulcers, strengthening ORGO’s clinical and commercial position. ORGO faces a 25–38% revenue decline in 2026 from CMS reimbursement changes, but RCT-backed evidence de-risks coverage and supports a recovery thesis into 2027. With ORGO's EV/sales at 0.7x and EV/EBITDA at 5.4x trailing, the market is discounting severe but temporary revenue pressure, offering clear re-rating upside if reimbursement stabilizes. Read the full article on Seeking Alpha
ORGO: FDA Rolling BLA For Knee Osteoarthritis Will Support Bullish Outlook
Analysts have maintained their $8.00 price target on Organogenesis Holdings, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Organogenesis completed a planned Type B meeting with the FDA, securing confirmation to begin a rolling Biologics License Application for ReNu, with the filing expected to start before the end of December (Key Developments).ORGO: FDA BLA Progress For Knee Osteoarthritis Will Support Bullish Outlook
Analysts have slightly trimmed their price targets on Organogenesis Holdings, citing updated assumptions that include a modestly higher discount rate, slightly stronger revenue growth and profit margin estimates, and a somewhat lower future P/E multiple. What's in the News Organogenesis Holdings reported a successful Type B meeting with the FDA that cleared the way to start a rolling Biologics License Application, or BLA, for its ReNu product, with filing planned before the end of December (Key Developments).ORGO: FDA Rolling Submission For Knee Osteoarthritis Therapy Will Support Bullish Outlook
Analysts have nudged their price target on Organogenesis Holdings higher to US$8.00, citing slightly firmer assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Completed a planned Type B meeting with the FDA, receiving confirmation to initiate a rolling Biologics License Application for ReNu, targeted before the end of December (Key Developments).The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28%
Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shareholders won't be pleased to see that the share price has had a very...Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...ORGO: Regulatory Momentum For Knee Osteoarthritis Therapy Will Support Bullish Outlook
Analysts have raised their fair value estimate for Organogenesis Holdings from US$7.00 to US$8.00, citing changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E estimates as key drivers of the updated price target. What's in the News Completed a planned Type-B meeting with the FDA, with confirmation to begin a rolling Biologics License Application (BLA) for ReNu before the end of December (Key Developments).
ORGO: Upcoming Knee Osteoarthritis BLA Filing Will Drive Long Term Upside
Analysts have modestly lifted their price target on Organogenesis Holdings to 8.50 dollars from 8.50 dollars, reflecting slightly higher long term profitability and valuation assumptions despite essentially unchanged growth and fair value estimates. What's in the News Completed a planned Type B FDA meeting confirming the path to initiate a rolling Biologics License Application for ReNu for knee osteoarthritis before the end of December, which advances the regulatory strategy for this lead asset (Key Developments) Raised 2025 guidance and projected net product revenue between 500.0 million dollars and 525.0 million dollars, an increase of 4% to 9% year over year, with expected net income between 8.6 million dollars and 25.4 million dollars (Key Developments) Reported that the second Phase 3 randomized controlled trial of ReNu in knee osteoarthritis did not meet its primary endpoint for statistical significance, but showed numerical pain reduction improvements and maintained a favorable safety profile, supporting plans for an FDA BLA filing (Key Developments) Highlighted that ReNu has been evaluated in three large randomized controlled trials involving more than 1,300 patients and previously received FDA Regenerative Medicine Advanced Therapy designation for knee osteoarthritis, which reinforces its clinical and regulatory foundation (Key Developments) Valuation Changes Fair Value Estimate remained unchanged at 8.50 dollars per share, indicating a stable view of intrinsic equity value.ORGO: Upcoming Knee Osteoarthritis FDA Filing Will Support Future Share Price Expansion
Analysts have modestly raised their price target on Organogenesis Holdings to 8.50 dollars from 7.50 dollars, citing a slightly higher assumed future price to earnings multiple that more than offsets minor adjustments to the discount rate and margin assumptions. What's in the News Raised 2025 earnings guidance, expecting net product revenue of 500 million to 525 million dollars, up 4% to 9% year over year from 482 million dollars in 2024, with projected net income between 8.6 million and 25.4 million dollars (company guidance).Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Shares Bounce 27% But Its Business Still Trails The Industry
Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have had a really impressive month, gaining 27% after a shaky period...ORGO: Anticipated 2025 Guidance And Promising Data Will Support Share Price Expansion
Analysts have revised their price target for Organogenesis Holdings downward from $8.00 to $7.50. This reflects a tempered outlook based on updated forecasts for revenue growth and profit margins.CMS Reform And Capacity Expansion Will Unlock Long Term Value
With no change in key metrics such as Future P/E and Net Profit Margin, the consensus analyst price target for Organogenesis Holdings remains steady at $8.00. What's in the News Organogenesis updated full-year 2025 guidance: expects net product revenue between $480 million and $510 million (roughly flat to 6% growth) and net income (loss) ranging from a $6.4 million loss to a $16.4 million profit.Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have been powering on, with a gain of...
LCD Delays And ReNu Progress Will Unlock Market Potential
Delay in LCDs implementation offers a chance to capitalize on demand, boosting near-term revenue and market share for key products.There's No Escaping Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Muted Revenues Despite A 69% Share Price Rise
The Organogenesis Holdings Inc. ( NASDAQ:ORGO ) share price has done very well over the last month, posting an...Organogenesis: Lurking Disruption With Recovery To Follow
Summary Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025. Liquidity is adequate and excellent potential for acquisition on expected pullbacks. Read the full article on Seeking AlphaWhy Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S
Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong...We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope
Key Insights Organogenesis Holdings to hold its Annual General Meeting on 20th of June Salary of US$908.7k is part of...Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Summary Organogenesis has two disproportionate segments, with Surgical and Sports Medicine making up a small portion of revenues. The company's pipeline candidate, ReNu, has the potential to boost Surgical and Sports Medicine revenues. In recent years, Organogenesis has generated inconsistent earnings and may not need to raise cash before launching ReNu. Read the full article on Seeking AlphaInvestors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) recent soft profit numbers didn't appear to worry shareholders, as the...Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Rendement pour les actionnaires
| ORGO | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 4.3% | 1.0% | 1.3% |
| 1Y | -7.3% | 34.2% | 27.7% |
Rendement vs Industrie: ORGO a sous-performé le secteur US Biotechs qui a rapporté 34.2 % au cours de l'année écoulée.
Rendement vs marché: ORGO a sous-performé le marché US qui a rapporté 27.7 % au cours de l'année écoulée.
Volatilité des prix
| ORGO volatility | |
|---|---|
| ORGO Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Cours de l'action stable: ORGO n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de ORGO ( 8% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| n/a | 854 | Gary Gillheeney | organogenesis.com |
Organogenesis Holdings Inc. est une société de médecine régénérative qui développe, fabrique et commercialise des produits pour les marchés du traitement avancé des plaies, de la chirurgie et de la médecine sportive aux États-Unis. Ses produits de soins avancés des plaies comprennent Affinity et Novachor, qui sont des allogreffes placentaires d'amnios et de chorion utilisées dans le traitement des plaies chroniques et aiguës comme barrières protectrices et échafaudages de matrice extracellulaire (ECM) ; Apligraf, un substitut cutané bi-couche bio-ingénierie pour le traitement des ulcères veineux de la jambe et des ulcères du pied diabétique (UPD) ; Dermagraft, un substitut dermique cultivé à partir de fibroblastes dermiques humains pour le traitement des UPD ; NuShield, une allogreffe placentaire déshydratée et une barrière chirurgicale pour fournir une barrière protectrice et un échafaudage ECM pour soutenir la cicatrisation naturelle ; PuraPly Antimicrobial (AM) et PuraPly SX, qui sont des barrières antimicrobiennes pour la gestion des plaies ouvertes en milieu chirurgical ; et CYGNUS Dual, VIA Matrix, et SimpliMax sont des greffes de tissu placentaire utilisées pour traiter les plaies chroniques et aiguës qui peuvent être stockées à température ambiante. La société propose également PuraPly MZ, une version micronisée de PuraPly pour le traitement des plaies ouvertes en milieu chirurgical ; PuraForce, une matrice chirurgicale de collagène porcin bio-ingénierie pour les applications de renforcement des tissus mous ; FortiShield, une matrice de plaie biosynthétique utilisée comme couverture protectrice temporaire ; et TransCyte, un échafaudage tissulaire bio-ingénierie qui favorise la cicatrisation des brûlures.
Organogenesis Holdings Inc. Résumé des fondamentaux
| ORGO statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$342.27m |
| Bénéfices(TTM) | -US$14.55m |
| Recettes(TTM) | US$514.70m |
Le site ORGO est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ORGO compte de résultat (TTM) | |
|---|---|
| Recettes | US$514.70m |
| Coût des recettes | US$134.39m |
| Marge brute | US$380.31m |
| Autres dépenses | US$394.86m |
| Les revenus | -US$14.55m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.11 |
| Marge brute | 73.89% |
| Marge bénéficiaire nette | -2.83% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de ORGO?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/27 16:13 |
| Cours de l'action en fin de journée | 2026/05/27 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Organogenesis Holdings Inc. est couverte par 7 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Gorman | BTIG |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Richard Newitter | Leerink Partners LLC |